ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintSite TitleTitle ChevronIcon Twitter
Retail Trade

Sundrug Co., Ltd.

Business Summary

Sundrug Co., Ltd. engages in the pharmaceutical business. It operates through the Drug Store and Discount Store segments. The Drug Store segment sells pharmaceutical products, cosmetics, and general merchandise. The Discount Store segment offers household goods and food products. The company was founded by Yukimasa Tada in December 1957 and is headquartered in Tokyo, Japan.

Financial Highlights

Mar 2020 JPYUSD
Revenue617,769M5,681.90M
Gross Profit154,619M1,422.10M
Operating income36,606M336.68M
Income before tax34,648M318.67M
Net income23,692M217.90M
EBITDA44,965M413.56M
Diluted EPS202.661.86
Dividends Per Share680.62
Total Assets284,276M2,633.28M
Total liabilities97,452M902.70M
Total equity186,822M1,730.55M
Operating cash flow32,274M296.83M
Currency in JPYCurrency in USD

Historical Data

 Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020
Revenue 503,773M 528,394M 564,215M 588,069M 617,769M
Gross Profit 124,119M 130,748M 140,959M 147,178M 154,619M
Operating income 33,025M 34,056M 36,081M 35,234M 36,606M
Income before tax 33,277M 34,424M 36,598M 35,071M 34,648M
Net income 21,569M 23,312M 24,829M 23,933M 23,692M
EBITDA 39,444M 41,335M 43,869M 43,476M 44,965M
Diluted EPS 178.42 197.31 212.30 204.75 202.66
Dividends Per Share 42.50 50 60 66 68
Total Assets 217,507M 221,458M 246,619M 262,195M 284,276M
Total liabilities 84,223M 85,121M 91,789M 91,137M 97,452M
Total equity 133,284M 136,335M 154,828M 171,055M 186,822M
Operating cash flow 33,574M 28,226M 36,148M 31,091M 32,274M
 Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020
Revenue 4,195.16M 4,879.54M 5,090.70M 5,302.95M 5,681.90M
Gross Profit 1,033.59M 1,207.41M 1,271.82M 1,327.18M 1,422.10M
Operating income 275.01M 314.49M 325.54M 317.72M 336.68M
Income before tax 277.11M 317.89M 330.21M 316.25M 318.67M
Net income 179.61M 215.27M 224.02M 215.81M 217.90M
EBITDA 328.46M 381.71M 395.81M 392.04M 413.56M
Diluted EPS 1.48 1.82 1.91 1.84 1.86
Dividends Per Share 0.35 0.46 0.54 0.59 0.62
Total Assets 1,935.20M 1,987.41M 2,318.93M 2,368.83M 2,633.28M
Total liabilities 749.34M 763.89M 863.08M 823.39M 902.70M
Total equity 1,185.85M 1,223.50M 1,455.83M 1,545.42M 1,730.55M
Operating cash flow 279.58M 260.65M 326.15M 280.36M 296.83M

Valuation Measures

Mar 2020
PER17.07
ROA8.67%
ROE13.24%
Operating margin5.92%
Profit margin3.83%

Key executives

  • President & Representative Director: Hiroshi Sadakata
  • Director & General Manager-Administration: Naoki Tada
  • Manager-Administration: Yoshinobu Kato

Shareholders

  • TADA NAOKI /SUNDRUG/ (39.2%)
  • Fidelity Management & Research Co. LLC (4.0%)
  • Massachusetts Financial Services Co. (3.4%)
  • Sundrug Co., Ltd. (2.0%)
  • Nomura Asset Management Co., Ltd. (1.8%)
  • TADA TAKASHI (1.8%)
  • The Vanguard Group, Inc. (1.6%)
  • Templeton Global Advisors Ltd. (1.2%)
  • Norges Bank Investment Management (1.0%)
  • BlackRock Fund Advisors (0.9%)

Contact Details

Related Companies

  • Sundrug Plus KK
  • Sundrug Tokai KK
  • Sun Drug Pharmacies KK
  • Seikoudo Yakkyoku KK
  • DIREX Corp.
  • Act KK

Competitors

  • Welcia Holdings Co., Ltd.
  • cocokara fine Inc.
Last Updated on 6 Aug, 2020

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends July 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media